CompletedPhase 2NCT00003058
Troglitazone in Treating Patients With Liposarcoma
Studying Liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Dana-Farber Cancer Institute
- Principal Investigator
- George D. Demetri, MDDana-Farber Cancer Institute
- Intervention
- troglitazone(drug)
- Enrollment
- 85 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 1997 – 2000
Study locations (2)
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003058 on ClinicalTrials.govOther trials for Liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07377747Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaAustralia and New Zealand Sarcoma Association
- RECRUITINGNCT06436846Genomic Risk in Retroperitoneal SarcomaFox Chase Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsAscentage Pharma Group Inc.
- RECRUITINGNCT04699292International Prospective Registry on Local Treatment Approaches in MLSThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04557449Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPfizer
- ACTIVE NOT RECRUITINGPHASE2NCT04438824Palbociclib and INCMGA00012 in People With Advanced LiposarcomaMemorial Sloan Kettering Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT03361436Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryOHSU Knight Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryM.D. Anderson Cancer Center